Publications by authors named "Laurie Herbst"
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Nivolumab, an anti-PD-1 monoclonal antibody, markedly improved overall survival in advanced renal cell carcinoma (RCC). However, ICIs can rarely trigger massive inflammation, a phenomenon characterized by rapid acceleration in radiographic tumor growth, the mechanisms underlying which are largely unknown.
View Article and Find Full Text PDFArticle Synopsis
- The use of gonadotropin-releasing hormone (GnRH) agonists in advanced prostate cancer can trigger a testosterone surge, leading to disease flare, which is concerning for patients.
- A common preventive strategy is to start antiandrogen treatment before GnRH agonist therapy, but this may be unsafe for patients at high risk of organ damage.
- Instead, using newer treatments like GnRH antagonists and CYP17 enzyme inhibitors can quickly lower testosterone levels without the side effects associated with antiandrogens, as demonstrated in three emergency cases.